戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 rugs [NSAIDs] or aspirin, 17 hormones, and 7 lipid-lowering agents).
2 mg/m2/d plus concomitant levothyroxine and a lipid-lowering agent.
3 l need for more effective and well tolerated lipid-lowering agents.
4 des as monotherapy or as an adjunct to other lipid-lowering agents.
5 lglutaryl coenzyme A reductase and effective lipid-lowering agents.
6 umed selection biases in the prescription of lipid-lowering agents.
7 ing to explore their efficacy beyond that of lipid-lowering agents.
8 lar morbidity and are refractory to standard lipid-lowering agents.
9 ry secondary prevention trials of adjunctive lipid-lowering agents.
10 for potential development as once-daily oral lipid-lowering agents.
11 clinical investigation of ASBT inhibitors as lipid-lowering agents.
12             In 252,460 patients treated with lipid-lowering agents, 24 cases of hospitalized rhabdomy
13  in all groups, changes were manageable with lipid-lowering agents and did not warrant discontinuatio
14 included as an outcome in clinical trials of lipid-lowering agents and lifestyle modifications.
15 justment for the propensity to be prescribed lipid-lowering agents and other potential confounders, p
16 , mechanical ventilation, gastrostomy tubes, lipid-lowering agents and symptom management.
17 glycerides), medication use (hypertensive or lipid-lowering agents), and self-reported health status.
18 self-reported use of aspirin, beta-blockers, lipid-lowering agents, and their combinations in all CAD
19 torial risk reduction with statins and other lipid-lowering agents, antihypertensive therapies, and a
20                                              Lipid-lowering agents are known to reduce long-term mort
21                                   Additional lipid-lowering agents are needed to fulfill an unmet med
22 stimates of rhabdomyolysis risk with various lipid-lowering agents are not available.
23                                              Lipid-lowering agents are widely prescribed in the Unite
24 ntion, including aspirin, beta-blockers, and lipid-lowering agents, are underused in these women, esp
25              Subsequent use of statin, other lipid-lowering agents, aspirin, and angiotensin-converti
26 blocker, and 20% to 25% were not receiving a lipid-lowering agent at 90 days after the index test.
27 her potential confounders, prescription of a lipid-lowering agent at discharge remained associated wi
28 ercury II-Compare the Efficacy and Safety of Lipid Lowering Agents Atorvastatin and Simvastatin With
29                                  Each of the lipid-lowering agents available today can cause myopathy
30                            Further trials of lipid-lowering agents beyond statins will be required in
31 ant differences in other lipids, BMI, use of lipid lowering agents, blood pressure, or smoking status
32 ibility that S1P inhibitors may be effective lipid-lowering agents, but they suggest that nearly comp
33                          Although most other lipid-lowering agents can be used safely with statins in
34                                     The only lipid-lowering agent currently available that specifical
35         Fenofibrate, a PPARalpha agonist and lipid-lowering agent, decreases amputation incidence in
36             Fenofibrate, a PPARa agonist and lipid-lowering agent, decreases amputation incidence in
37          The reduction of coronary events by lipid-lowering agents despite only modest luminal change
38 The recent FIELD study demonstrated that the lipid-lowering agent fenofibrate significantly reduces t
39              Conversely, participants taking lipid-lowering agents had a lower risk of receiving a ma
40                                        While lipid-lowering agents had no significant impact on the N
41 et drugs, beta-blockers, ACE inhibitors, and lipid-lowering agents, have proven efficacy in reducing
42 equently, thyromimetic drugs hold promise as lipid-lowering agents if adverse effects can be avoided.
43  alpha ligand that has been widely used as a lipid-lowering agent in the treatment of hypertriglyceri
44               Guidelines recommend nonstatin lipid-lowering agents in patients at very high risk for
45              Preliminary trials suggest that lipid-lowering agents, including statins, may be useful
46 IV infection include lifestyle modification, lipid-lowering agents, insulin sensitizers, and treatmen
47 e implications regarding the clinical use of lipid-lowering agents, like fibric acids, which can acti
48  and older: all individuals who had received lipid-lowering agents (LLAs); all individuals with a cli
49                                              Lipid-lowering agents may not reduce the incidence of ac
50                               Treatment with lipid-lowering agents may reduce risk of death following
51 s Heart Study participants who were using no lipid-lowering agent (n = 2,124) or using only a statin
52                               List prices of lipid-lowering agents (n = 11) increased by 278% and net
53 te coronary syndromes who were discharged on lipid-lowering agents (n=3653) with those who were not (
54 reviously: greater use of and more effective lipid-lowering agents, no significant weight gain, no di
55          Furthermore, neither simvastatin (a lipid lowering agent) nor cytochalasin D (an inhibitor o
56  A) reductase inhibitors (statins) and other lipid-lowering agents on dementia.
57            Bexarotene patients also received lipid-lowering agents on or before day 1.
58 ted to the lipid pathway, and the effects of lipid-lowering agents on reducing the incidence of OA.
59  in those who used systemic corticosteroids, lipid-lowering agents, or testosterone; those who exerci
60 or antiplatelets/anticoagulants (p<0.05) and lipid-lowering agents (p<0.001) and were maintained at 1
61 rs, and antithrombotic agents in addition to lipid-lowering agents, reduce events, and this may be at
62 atients with type 2 diabetes, treatment with lipid-lowering agents reduces cardiovascular risk.
63            The advent of the statin class of lipid-lowering agents represented a major advance, becau
64                     Combination therapy with lipid-lowering agents that act via a complementary pathw
65                     In patients treated with lipid-lowering agents, the vasodilator response to acety
66 4, the British government decided to allow a lipid-lowering agent to be sold as an over-the-counter m
67  therapy and selection of antithrombotic and lipid-lowering agents to attenuate atherosclerotic disea
68 ity, SBP, proportion of antihypertensive and lipid-lowering agent use and with decreasing HDL-cholest
69  emission tomography, changes in aspirin and lipid-lowering agent use was greater after computed tomo
70                               Treatment with lipid-lowering agents was associated with lower crude mo
71 ry of medicines, including statins and other lipid-lowering agents, was collected at both assessments
72 n of antihypertensive agents, diuretics, and lipid lowering agents were also studied.
73 that compared statins with another statin or lipid-lowering agent were excluded.
74 ized by very low LDL-C, analyses trials with lipid-lowering agents where patients attained very low L
75 G-CoA) reductase, also known as statins, are lipid-lowering agents widely used in the prevention of c
76 ts have been made to identify HCA2 targeting lipid lowering agents with fewer adverse effects, despit
77    Guidelines recommend combining additional lipid-lowering agents with a complementary mode of actio